Investigation of Serum Interleukin-10 & Tumor Necrosis Factor (TNF-a) Levels in Celiac Disease Patients
DOI:
https://doi.org/10.36320/ajb/v17.i1.18911Keywords:
tumor necrosis factor alpha (TNFα), anti-inflammatory, Interleukin-10, Celiac Disease, Anti-Tissue TransglutaminaseAbstract
In genetically predisposed subjects, gluten can trigger (celiac disease), an autoimmune syndrome affecting the small intestine, leading to immune reactions that damage the colon and cause various symptoms. The investigation was aimed at measuring serum levels of tissue transglutaminase both (Immunoglobulin IgG, IgA), Interleukin-10 with Tumor Necrosis Factor-alpha in patients confirmed with celiac disease (CD). The research utilized a case-control methodology at AL-Sadder Medical Center, involving a sample of 158 specimens. It included 79 individuals with coeliac disease and 79 normal controls of the identical ages (18-50) along with sexuality. Blood serum for tissue-transglutaminase (t.TG) immunoglobulins (IgG, IgA) levels were measured using ChLIA, while interleukin-10 (IL-10), and tumor necrosis factor-alpha were assessed using an ELISA kit. The current investigation revealed that patients exhibited significantly elevated levels of IL-10 nearly 2.5-fold higher (46.875 ± 24.533) compared to the control group (18.597 ± 8.324), with a p-value of less than 0.001, indicating a statistically significant difference. Furthermore, the findings demonstrated that Tumor Necrosis Factor-alpha (TNF-α) levels were substantially higher in patients with celiac disease (43.985 ± 21.782), nearly triple the levels observed in the control group (15.510 ± 12.294), also with a p-value of less than 0.001. There was a significant increase in the levels of Tumor Necrosis Factor-Alpha (TNF-α) and Interleukin-10 in patients confirmed with celiac disease. Additionally, the investigation identified a positive correlations significantly among TNF-α and tissue transglutaminase (t.TG) IgG, as well as between t.TG IgA and Interleukin-10.
Downloads
References
Bentley, D., Mannino, M., Manchester, M., Camillo, P., Bernhard, T., & Malcolm, R. (2025). controlled , multiple dose , parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease. Clinical and Translational Science, July 2024, 1–7. https://doi.org/10.1111/cts.13901.
Aitella, E., Cozzolino, D., Ginaldi, L., & Romano, C. (2025). Celiac Disease: A Transitional Point of View. Nutrients, 17(2). https://doi.org/10.3390/nu17020234.
Hedesh, M., Maharat, Z., Khalaji, A., Pazouki, L., & Dooraki, S. (2024). Early detection of celiac disease through its common symptoms using machine learning algorithms. Journal of Clinical Images and Medical Case Reports, 5(3), 2915. https://doi.org/10.52768/2766-7820/2915.
Jawad, M. M., Hasan, A. A., & Farman, H. A. (2020). Role of selective cytokines in the pathophysiology of patients with celiac disease. Indian Journal of Forensic Medicine and Toxicology, 14(4), 1888–1893. https://doi.org/10.37506/ijfmt.v14i4.11820.
Dahal-Koirala, S., Risnes, L. F., & Sollid, L. M. (2022). Pathogenesis of coeliac disease–a disorder driven by gluten-specific CD4+ T cells. In Coeliac Disease and Gluten-Related Disorders (pp. 41-68). Academic Press.. https://doi.org/https://doi.org/10.1016/B978-0-12-821571-5.00007-6.
Hadjivassiliou, M., Trott, N., Hoggard, N., & Sanders, D. S. (2024). Sensory Symptoms without Structural Pathology in Patients with Gluten Sensitivity. Nutrients, 16(8). https://doi.org/10.3390/nu16081209.
Eidan, J. S., & Mubark, H. A. (2024a). Assessment of Levels of Interferon Gamma ( IFN- γ ) and Interleukin-15 as markers in Patients with Celiac Disease. Medical Science Journal for Advance Research, 5(3), 1–8.
Romero-Adrián, T. (2016). Celiac disease: Participation of Cytokines and Other Factors in the Immune Response. Journal of Gastrointestinal Disorders and Liver Function, 1, 1–6. https://doi.org/10.15436/2471-0601.15.005.
Veenbergen, S., & Samsom, J. N. (2012). Maintenance of small intestinal and colonic tolerance by IL-10-producing regulatory T cell subsets. Current Opinion in Immunology, 24(3), 269–276. https://doi.org/10.1016/j.coi.2012.03.004.
Chavez-Dominguez, R., Perez-Medina, M., Aguilar-Cazares, D., Galicia-Velasco, M., Meneses-Flores, M., Islas-Vazquez, L., ... & Lopez-Gonzalez, J. S. (2021). Old and new players of inflammation and their relationship with cancer development. Frontiers in Oncology, 11, 722999. https://doi.org/10.3389/fonc.2021.722999.
Jahdkaran, M., Asri, N., Esmaily, H., & Rostami-Nejad, M. (2024). Potential of nutraceuticals in celiac disease. Tissue Barriers, 2374628. https://doi.org/10.1080/21688370.2024.2374628.
Abed, R. M., Yaaqoob, L. A., Alwan, I. A., Samir, H. F., & Jasim, R. A. (2018). Evaluation of some serum cytokine and adipokines profile in Iraqi celiac patients before and after treatment. Journal of Pharmacy and Biological Sciences, 12(6), 36–41. https://doi.org/10.9790/3008-1206063641.
Cinova, J., Palova-Jelinkova, L., Smythies, L. E., Černá, M., Pecharova, B., Dvořák, M., Fruhauf, P., Tlaskalova-Hogenova, H., Smith, P. D., & Tučková, L. (2007). Gliadin peptides activate blood monocytes from patients with celiac disease. Journal of Clinical Immunology, 27, 201–209. https://doi.org/10.1007/s10875-006-9061-z.
Eidan, J. S., & Mubark, H. A. (2024b). Assessment of Serum Levels of Anti-Gliadin (IgA and IgG) and Interleukin-2 in Patients with Celiac Disease. Medical Science Journal for Advance Research, 5(2).
Alrazaaq, A. A. A.-. (2023). Role of pro and Anti-inflammatory Cytokines in Celiac Disease, Non-Celiac. kufa university. 113p.
Mohammed, N. (2023). The Assessment of Interleukin-15 and Interleukin-21 Gene Expression and Serum Level in Celiac Disease Prevalence Patients. CME Journal Geriatric Medicine, 16, 1–7. https://doi.org/10.61336/cmejgm.2024.v015.i01.001.
Ajdani, M., Mortazavi, N., Besharat, S., Mohammadi, S., Amiriani, T., Sohrabi, A., Norouzi, A., & Edris, G. (2022). Serum and salivary tissue transglutaminase IGA (tTG-IGA) level in celiac patients. BMC Gastroenterology, 22(1), 1–7. https://doi.org/10.1186/s12876-022-02456-x.
Ciacci, C., Bai, J. C., Holmes, G., Al-Toma, A., Biagi, F., Carroccio, A., ... & Zanoni, G. (2023). Serum anti-tissue transglutaminase IgA and prediction of duodenal villous atrophy in adults with suspected coeliac disease without IgA deficiency (Bi. A. CeD): a multicentre, prospective cohort study. The Lancet Gastroenterology & Hepatology, 8(11), 1005-1014. https://doi.org/10.1016/S2468-1253(23)00205-4.
Iervasi, E., Auricchio, R., Strangio, A., Greco, L., & Saverino, D. (2020). Serum IL-21 levels from celiac disease patients correlates with anti-tTG IgA autoantibodies and mucosal damage. Autoimmunity, 53(4), 225–230. https://doi.org/10.1080/08916934.2020.1736047.
Caio, G., Volta, U., Sapone, A., Leffler, D. A., De Giorgio, R., Catassi, C., & Fasano, A. (2020). Celiac disease: A comprehensive current review. BMC Medicine, 17(1), 1–20. https://doi.org/10.1186/s12916-019-1380-z.
Idan, J. S. (2024). Evaluation of Pro-inflammatory Cytokines IL- 2 , IL-15 and Interferon Gamma in Patients with Celiac Disease. 155p.
Absah, I., Rishi, A. R., Gebrail, R., Snyder, M. R., & Murray, J. A. (2017). Lack of Utility of Anti-tTG IgG to Diagnose Celiac Disease When Anti-tTG IgA Is Negative. Journal of Pediatric Gastroenterology and Nutrition, 64(5), 726–729. https://doi.org/10.1097/MPG.0000000000001351.
Maglio, M., & Troncone, R. (2020). Intestinal Anti-tissue Transglutaminase2 Autoantibodies: Pathogenic and Clinical Implications for Celiac Disease. Frontiers in Nutrition, 7(May), 1–12. https://doi.org/10.3389/fnut.2020.00073.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mr. Murtadha Alaa Hilal, Prof. Dr. Wasan Sami Hameed
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
